Aktis Oncology
PublicAktis Oncology is now publicly traded
The data on this page reflects Aktis Oncology's private-market history up to the point it went public, including its funding rounds, valuation, and investors.
Went Public
Jan 13, 2026
Last Round
Series B
Sep 30, 2024
Total Funding Raised
$696.4M
Company Overview
Aktis Oncology is a biotechnology company that develops targeted radiopharmaceuticals for the treatment of various solid tumor cancers.
Sector
Biotech
Verticals
Life Sciences, Oncology
AI Layer
Application
Keywords
Aktis Oncology Comparables
Compare Aktis Oncology with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Ratio Therapeutics Inc. | 87% | |
| Alpha-9 Oncology | 87% | |
| Radiopharm Theranostics | 83% |
For institutional investors. Book with your work email.
Aktis Oncology Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| IPO | Jan 13, 2026 | ||||
| Series B | Sep 30, 2024 | ||||
| Series A Extension | Aug 25, 2022 | ||||
| Series A | Mar 18, 2021 |
For institutional investors. Book with your work email.
Key People
Founding team and executive leadership
For institutional investors. Book with your work email.
Aktis Oncology Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| EcoR1 Capital | Series B, Series A, Series A Extension |
| Andreessen Horowitz | IPO |
| Janus Henderson Group | Series B |
| MPM Capital | Series B, Series A Extension, Series A |
| RA Capital Management | Series B |
| TCG Crossover | Series A, Series B, Series A Extension |
| A. M. Pappas & Associates | Series A Extension |
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingSep 9, 2026
Aktis Oncology, Inc. has a discovery collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside its proprietary pipeline.
- has_revenueAug 13, 2026
Aktis Oncology, Inc. reported quarterly revenue of $3.38M on Aug 13th '26, exceeding analyst estimates of $2.14 million.
For institutional investors. Book with your work email.
Aktis Oncology Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.